one8zero8 LLC Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

one8zero8 LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 3,500 shares of the medical equipment provider's stock, valued at approximately $370,000.

A number of other institutional investors have also added to or reduced their stakes in ZBH. Dunhill Financial LLC grew its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $25,000. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet during the third quarter worth $35,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $39,000. Finally, OFI Invest Asset Management bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $40,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.95% of the company's stock.

Remove Ads

Analysts Set New Price Targets

ZBH has been the subject of several recent research reports. JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Barclays decreased their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. JMP Securities restated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Stock Performance

NYSE:ZBH traded down $1.19 during trading hours on Thursday, reaching $111.72. The company had a trading volume of 1,431,382 shares, compared to its average volume of 1,489,265. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a market cap of $22.24 billion, a PE ratio of 25.11, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The business's 50 day moving average price is $106.41 and its 200-day moving average price is $106.93. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the business posted $2.20 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.